Markets
Alerts
F&O
MF
Reports
Screeners
Subscribe
Superstars
Portfolio
Watchlist
Insider Trades
Results
Data Downloader
Events Calendar
What's New
Explore
FAQs
Widgets
More
Search stocks
IND
USA
IND
IND
×
Close
IND
USA
Stocks
Futures & Options
Mutual Funds
News
Fundamentals
Reports
Corporate Actions
Alerts
Shareholding
Overview
Buy Sell Zone
F&O
Financials
News
All
News
Earnings Calls
Corporate Announcements
Research Reports
Reports
Technicals
Technicals
Share Price History
Delivery
Shareholding
Shareholding
Monthly MF Holdings
Bulk Block Deals
Insider Trading & SAST
Deals
Bulk Block Deals
Insider Trading & SAST
Corporate Actions
All
Dividend
Bonus
Split
Rights
Board Meetings
Alerts
(1)
About
Glenmark Pharmaceuticals Ltd.
NSE: GLENMARK
|
BSE: 532296
|
ISIN: INE935A01035
|
Industry: Pharmaceuticals
Dividend
|
Strong Performer, Getting Expensive
2127.7000
-3.20
(
-0.15
%)
NSE
Sep 11, 2025
15:31 PM
66.81% Gain from 52W Low
Volume:
737.1K
Share on Facebook
Tweet
Share on LinkedIn
Share via Whatsapp
Glenmark Pharmaceuticals Ltd.
31 May 2022
Dividend
2127.70
-0.15%
GLENMARK PHARMACEUTI
Accumulate:
Glenmark Pharmaceuticals Ltd.
by
Prabhudas Lilladhar
Target: 450
Target
Prabhudas Lilladhar
Geojit BNP Paribas increased Accumulate price target of Glenmark Pharmaceuticals Ltd. to 2306.0 on 09 Sep, 2025.
More from Glenmark Pharmaceuticals Ltd.
Recommended
Market closes higher, Tega Industries to buy Molycop with Apollo Funds in a $1.5 bn deal
Trendlyne Marketwatch |
11 Sep 2025, 04:07PM
India’s IPO story in 2025: Investors go selective, backing quality over hype
The Baseline |
11 Sep 2025, 03:50PM
Earnings Call Transcript - Q4FY20 for Glenmark Pharmaceuticals
|
29 Jun 2020